Furthermore, MA itself is associated with impairment of hypoxic pulmonary vasoconstriction, alterations in oxyhemoglobin dissociation, reduced cardiac output, cardiac dysrhythmias, and increased mortality. [4] From a pathophysiological point of view, restoring the physiological pH or even inducing a mild metabolic acidosis should cause a favorable shifts in the oxygen-dissociation curve and a stimulation of chemoreceptors, which in turn induces an increase in minute ventilation. [5] Acetazolamide (ACET), a nonspecific carbonic anhydrase (CA) inhibitor, is one of the drugs employed to reverse MA. [5] In this issue, we publish the results of a case-control study designed to evaluate the impact of ACET in COPD exacerbation requiring IMV.
ACET promotes renal excretion of bicarbonate along with strong cations by inhibition of CA IV in the proximal tubules. The mild metabolic acidosis that results can be explained both by the Henderson-Hasselbalch equation (the loss of bicarbonate determines the fall in pH) and by the physicochemical approach described by Stewart (the decrease in SID, due to a renal excretion of sodium without chloride, resulting in a relative increase in serum chloride, determines the decrease in pH) [6] ACET acts also on CA II, which plays a role in regulating gas exchange in the lung and in the erythrocyte and might modulate the activity of slowly adapting pulmonary stretch receptors (SARs), which seem to play a role in the control of respiratory rate and tidal volume. [7] In last years, ACET was proposed as an adjunctive treatment for ventilatory failure due to COPD. 250-500 mg of ACET induce an increase in minute ventilation by 10% to 20% in healthy subjects and an increase in oxygen saturation of hemoglobin by 3% to 6% in subjects with hypoxemia. [6, 7] The study published in this issue concluded that 500 mg per day of ACET reverses MA, reduces PaCO 2 but has no effects on PaO 2 /FiO 2 ratio and the duration of mechanical ventilation, ICU mortality and ICU staying.
These results match with previously published clinical trials. [6] [7] [8] Currently, ACET given to patients with both COPD and MA appears to be only a cosmetic.
We can speculate on why ACET is, for the moment, only a cosmetic and not a therapy.
First of all, the tissue compartmentalization of CA isoforms and the low selectivity of ACET may explain, in part, the complexity of the effect of the drug in patients with COPD and, in turn, might explain why the efficacy of ACET is so moderate in the critically ill patient with COPD. Another possible explanation is that the usually employed doses of the drug are insufficient to improve the clinical situation.
